Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[3]
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[4]
^Toronto Notes: Comprehensive medical reference and review for the Medical Council of Canada Qualifying Exam Part I and the United States Medical Licensing Exam Step 2 (32nd ed.). Toronto, Ontario, Canada.: Toronto Notes for Medical Students, Inc. ISBN 978-1-927363-26-3.
^"ReoPro Abciximab" (PDF). Janssen Pharmaceutical Companies. U.S. Food and Drug Administration. August 2019.
^"Abciximab". Drugs.com. Archived from the original on 20 April 2010. Retrieved 13 March 2010.
^"International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 7 (4). 1993. Archived from the original (PDF) on June 27, 2004.
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro,...
Churchill Livingstone. pp. 241, for the examples infliximab, basiliximab, abciximab, daclizumab, palivusamab, gemtuzumab, alemtuzumab and rituximab, and mechanism...
GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market. Eptifibatide...
Developed the drug that is recommended for all cardiac angioplasties (abciximab) 1974 Created the first MRI image of a living organism Discovered the...
Sakmar was acting-president from 2002.) Barry Coller, who invented the Abciximab, currently serves as the Vice President for Medical Affairs. In all, as...
g. insulin and human growth hormone), antibodies (e.g. infliximab and abciximab) and vaccines; antibodies and enzymes used in diagnostics; industrial...
points to the widely accepted pronunciation of any given INN. For example, abciximab is predictably /æbˈsɪksɪmæb/, because for INNs ending in -ciximab, the...
for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA)...
stem. Examples of chimeric antibodies approved for human therapy include abciximab (ReoPro), basiliximab (Simulect), cetuximab (Erbitux), infliximab (Remicade)...
adalumab (ada-li-u-mab). After 2017, it would be adalimab (ada-li-mab). Abciximab is a commonly used medication to prevent platelets from clumping together...
Drug Mechanism of action Indications Toxicity Abciximab A monoclonal antibody that binds to the glycoprotein receptor IIb/IIIa on activated platelets...
date Route Type Target Indication (Targeted disease) BLA STN Drug Label abciximab ReoPro Centocor 12/22/1994 intravenous chimeric Fab GPIIb/IIIa Percutaneous...
(2003). "Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to...
by Jorge Benach Drugs that were developed by faculty of RSOM include: Abciximab (for cardiac angioplasty) by Barry S. Coller Doxycycline (for periodontal...
patients undergoing percutaneous coronary intervention, consisting of abciximab, eptifibatide and tirofiban. Patients presenting with ST elevation that...
Metzler H, Rehak P, März W, Halwachs-Baumann G. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost...
Global Information
(what is this?) (verify)